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Abstract
Telomere instability results from chromosome end loss (due to chromosome breakage at
one or both ends) or, more frequently, telomere dysfunction. Dysfunctional telomeres
arise when they lose their end-capping function or become critically short, which causes
chromosomal termini to behave like a DNA double-strand break. At the chromosomal
level, this phenomenon is visualized by using Fluorescence In Situ Hybridization (FISH),
as chromosomal aberrations directly involving terminal telomeric repeats: loss or dupli‐
cation of telomeric signals, association or fusion of telomeres of different chromosomes,
telomere sister chromatid exchanges, translocation or amplification of telomeric sequen‐
ces, and extrachromosomal telomeric signals. At the molecular level, telomere instability
arises due to the loss or modification of any of the components of the telomere (telomere
DNA, telomere-associated proteins or telomere RNA). Since telomeres play a fundamen‐
tal role in maintaining genomic stability, the study of telomere instability in cells exposed
to anticancer drugs is of great importance to understand the genomic instability associat‐
ed with chemotherapy regimens. In this chapter, we will summarize our current knowl‐
edge about telomere instability induced by anticancer drugs on mammalian cells.
Keywords: Telomere, telomere instability, telomere loss, telomere dysfunction, telomere
erosion, chemotherapy, anticancer drugs
1. Introduction
1.1. What are telomeres?
Classically defined as the chromosome ends, telomeres (from the Greek, telo = end, and mere
= part) [1] are nowadays defined as specialized nucleoprotein complexes localized at the
physical ends of linear eukaryotic chromosomes, that maintain their stability and integrity [2,
3]. They protect chromosomes from degradation, recombination or fusion, by preventing the
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ends of linear chromosomes from being recognized as DNA double-strand breaks (DSB) by
the DNA repair machinery, i.e., they distinguish natural DNA ends from DNA ends resulting
from breakage events [2, 3].
In all vertebrates, telomeres are composed of tandem arrays of short, repetitive G-rich
sequences (TTAGGG)n, oriented 5′ → 3′ towards the end of the chromosome, ending in an
essential 3′ single-stranded overhang that ranges in length from ~50 to 400 nt [4-6], bound by
a specialised multiprotein complex known as “shelterin” or telosome [7-9]. The length of the
double-stranded telomeric repeat varies greatly among species [2]. In normal human cells, the
DNA at each chromosome terminus spans 5-20 kb in length [6, 10, 11], terminating in a 3‟
single-stranded overhang 100-400 nt in length [10], whereas in human tumor cells, telomere
length varies from 1 to 20 kb [12-14].
The telosome is constituted by 6 proteins (POT1, TPP1. TIN2, TRF1, TRF2 and RAP1) and is
charged with protecting chromosome ends from activating a DNA damage response, inhibit‐
ing inappropriate repair mechanisms, and maintaining telomeric length and structure [7-9].
Besides telomeric repeats and shelterin, telomeres also comprise (UUAGGG)n-containing
RNA molecules (telomeric repeat-containing RNA or TERRA), a novel class of RNA for which
several functions have been suggested [15-18]. TERRA transcription occurs at most or all
chromosome ends and it is regulated by RNA surveillance factors and in response to changes
in telomere length. Therefore, telomeres are composed of DNA, proteins, and RNA. In addition
to the shelterin complex, many proteins involved in DNA repair are also associated with
telomeres [19].
Telomere length is maintained by a dynamic process of telomere shortening and lengthening.
Usually, telomere shortening occurs due to nucleolytic degradation and incomplete DNA
replication, due to the inability of lagging strand synthesis to completely replicate chromoso‐
mal ends (i.e., the so-called “end replication problem”) [9]. Telomere shortening is usually
prevented by telomerase, a reverse transcriptase-like enzyme containing an RNA subunit
(TERC, “Telomere RNA Component”) and a catalytic protein subunit called “Telomerase
Reverse Transcriptase” (TERT, “Telomere Reverse Transcriptase”) which works via an RNA
template -using exclusively single-strand 3‟ telomeric overhangs as primers- [9], by adding
telomeric repeats to the chromosome ends. Although repressed in the majority of normal
somatic cells (with the exception of a transient S phase activity thought to maintain the single-
stranded overhang]), telomerase is present in immortal cell lines, germline cells, stem cells,
activated lymphocytes, and most of the tumor cells analyzed so far [20, 21]. Telomerase activity
favors 3‟ overhangs over blunt DNA ends for an addition of telomere sequence, at least in
vitro [22, 23]. Loss of telomerase enzymatic function leads to progressive telomere shortening
over time, eventually resulting in the disappearance of detectable telomeric DNA and the
formation of end-to-end chromosome fusions, followed by growth arrest or cell death [24].
It has been suggested that TERRA may be involved in the regulation of telomerase activity
and that the accumulation of TERRA at telomeres can interfere with telomere replication,
leading to telomere loss [15-18]. Telomere elongation can also occur in the absence of telomer‐
ase through the so-called ALT (for ‘Alternative Lengthening of Telomeres’) mechanism, which
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involves homologous recombination between telomeres and has been described in several
tumor cells and immortalized cell lines [25].
The analysis of the short- and long-term chromosomal instability produced by anticancer
drugs is of great importance to understand the genomic instability associated with chemo‐
therapy regimens. Since telomeres play a fundamental role in maintaining chromosomal/
genomic stability, the study of telomere instability induced by antineoplastic drugs is of clinical
interest. Therefore, in this chapter, we will consider in detail the phenomenon of telomere
instability and summarize our current knowledge concerning the main data available about
telomere instability induced by anticancer drugs on mammalian cells. In the next section, we
will see what is telomere instability and how it can be generated in the cells.
2. What is telomere instability? Telomere loss, dysfunction and erosion
Telomere instability refers to the chromosomal instability caused either by the loss of the
chromosome ends (one or both) or the dysfunction of telomeres [26, 27]. These phenomena
can take place in the short (at first cell división after the induction of chromosome damage by
a given mutagen) or in the long term (in the progeny of the exposed cells). Once telomere
instability arises, the involved chromosomes tend to associate or fuse with each other [26, 27].
Chromosomal instability is usually defined as a delayed increase in the production of new
aberrations or a delayed appearance of excessive levels of aberrations in the clonal surviving
cells after exposure to a given mutagen [28]. However, whenever a chromosome lacks one or
both of its ends or suffers telomere dysfunction it becomes unstable, so we can refer to
chromosome -or more properly, telomere- instability to the one that arises since the first cell
division after the chromosome damage event at the telomeric region occurs.
Telomeric instability may arise when a chromosome, due to a break in one or both of its ends,
loses one or both telomeres (ie, becomes an "incomplete chromosome") and, therefore, the
chromosome end is exposed to enzymatic degradation or fuses with another chromosome end
or enters to what is called a breakage-fusion-bridge (BFB) cycle (see below for details). We refer
to this type of instability as telomere instability by telomere or chromosome end loss [26, 27,
29]. Alternatively, if one or both telomeres of the chromosome are excessively shortened, the
chromosome tends to associate or fuse with other damaged chromosomes. This shortening
can affect any of the four telomeres of a (metaphase) chromosome, resulting in duplication or
loss of telomeric signals (after Fluorescence In Situ Hybridization or FISH, each FISH signal
representing a block or specific set of telomeric sequences) [26, 29]. It may also be the case that
any of the telomeric proteins (the shelterin complex) or telomeric RNA be altered or lost. In all
these cases, we refer to telomeric instability by telomere dysfunction because the telomere has
lost its protective function, either by excessive shortening (termed "telomere erosion or
attrition") or by loss or alteration of the proteins or RNA associated with the telomeric DNA
[26]. This phenomenon can be studied at the cytogenetic level by telomere FISH and is visible
through telomeric chromosomal aberrations such as telomeric fusions, associations or loss or
duplication of telomeric signal [26, 29, 30].
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2.1. Telomere or chromosome end loss
As previously noted, true telomere loss is due to chromosome breakage at one or both ends of
the chromosome, and can generate chromosome instability, both by allowing degradation of
the ends of chromosomes and promoting chromosome fusions. Fusion can occur between sister
chromatids, or between different chromosomes if telomeres are lost in more than one of the
chromosomes of a given cell. Chromosome fusion results in chromosome instability through
the abovementioned BFB cycles [26, 27, 29], when chromosomes, after telomere loss, repeatedly
fuse and break for many cell generations. BFB cycles can continue for multiple cell generations,
leading to extensive chromosomal rearrangements, and terminate when the unstable chro‐
mosome eventually acquires a new telomere and so becomes stable [26, 27, 29]. BFB cycles
involving sister chromatid fusions result in several types of chromosome rearrangements,
including terminal deletions, inverted duplications, DNA amplification, duplicative and
nonreciprocal translocations, and dicentric chromosomes, all of which have been associated
with human cancer. Chromosomes lacking one telomere remain unstable until they are
capped, and lost telomeres after a BFB cycle can be acquired by several mechanisms, including
nonreciprocal translocation, duplication/translocation, subtelomeric duplication, or direct
telomere addition [26, 27, 29]. For a detailed description of BFB cycles see [26, 27].
2.2. Telomere dysfunction and erosion
As previously stated, dysfunctional telomeres arise when they lose their end-capping function
or become critically short (a phenomenon called telomere erosion or attrition), which causes
chromosomal termini to behave like a DSB [9, 31]. In effect, dysfunctional (uncapped or
shorten) telomeres are sensed as true DSB, according to the presence of DNA damage response
proteins at telomeres in senescent cells or shelterin deficient cells [32]. Therefore, dysfunctional
telomeres act as DSB, interfering with the correct rejoining of broken ends. Both telomeres and
DSB are DNA ends, and as such, both recruit many of the same proteins. As previously
mentioned, proteins governing the DNA damage response are intimately involved in the
regulation of telomeres, which undergo processing and structural changes that elicit a transient
DNA damage response [19]. Chromosomes with dysfunctional telomeres tend to fuse with
one another, producing dicentrics, which can give rise to the abovementioned BFB cycles [26,
27]. It must be taken into account that telomere shortening does not always mean telomere
dysfunction. Only when telomeric repeats loss gives rise to a defective telomere structure a
dysfunctional telomere appears. Thus, telomere erosion refers to a dysfunctional telomere
which became critically short, so it cannot function properly.
Telomere dysfunction at the chromosomal level is commonly assessed applying the telomere
FISH technique to metaphase chromosomes [26, 29, 30]. A normal metaphase chromosome
exhibits four telomeric signals, two at each end (one per chromatid). When the telomere
becomes dysfunctional, one or more of these telomeric signals are lost or duplicated [26, 29,
30]. The presence of chromosome ends with undetectable telomeric hybridization signals has
been shown to be a good indicator of critically short and probably dysfunctional telomeres in
mammalian cells [33-36]. It is important to mention that not all telomere involving chromo‐
somal aberrations imply telomere dysfunction, but only those ones directly involving terminal
telomeric repeats (see [26, 29] for details).
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Telomeres suppress the DNA damaging response, so dysfunctional telomeres activate DNA
damage checkpoints [19, 32]. In addition, dysfunctional telomeres induce metabolic and
mitochondrial compromise [37], promote carcinogenesis [38, 39], induce chromosome
instability [27], and triggers cellular senescence [40].
3. Factors promoting telomere instability
Several factors can promote telomere instability. Telomere instability due to true telomere loss
can be generated by any mutagen which breaks the chromosome and induces terminal
deletions, as shown by several studies (see [26] for review). This kind of instability gives rise
to the so-called “incomplete chromosome elements”, which comprise chromosomes without
one or both telomeres (incomplete chromosomes) and the acentric fragments resulting from
the breakage event (termed “terminal fragments”) [26, 29, 30].
Telomere instability due to telomere dysfunction can be generated in several ways [26].
Alterations in the shelterin complex or other telomere-binding proteins [7, 8, 41], some DNA
damage response proteins required for proper telomere protection [42], the structure of
telomeric DNA (loss of telomeric sequences, see below), the structure or activity of telomerase
[43], TERRA [15-18] or the enzymes helicases [44, 45] can give rise to dysfunctional telomeres.
All these factors are involved in the production of telomere-related chromosomal aberrations.
These aberrations have been described in detail elsewhere [26, 29, 30] and thus they will not
be considered in the present chapter. Moreover, dysfunctional telomeres may result as a
consequence of mutagen-induced telomeric DNA damage [26].
Referring to the relationship between telomere shortening and dysfunction, we must bear in
mind that, as previously mentioned, telomere length is maintained by a dynamic process of
telomere shortening and lengthening. Telomeres lose approximately 20-300 bp of repeat
sequences every cell division mainly due to the “end replication problem” [9]. This is the most
obvious mechanism for the loss of telomeric repeat sequences, i.e., attrition due to the failure
to compensate for the gradual loss of these repeats during cell division, and is termed repli‐
cative erosion or replicative shortening, which leads to replicative senescence of cells. Thus,
telomeres regulate the replicative life span of somatic cells, acting as a “mitotic clock”. There
is another kind of telomere shortening, termed “stress dependant shortening”, which is
produced by stress-inducing factors like radiation, oncogenes, oxidative damage within
telomeric DNA, chromosome end-specific exonuclease activity, and the lack of telomerase
activity [46-49]. Stress dependant shortening can lead to the loss of large blocks of telomeric
repeat sequences through different mechanisms, including recombination, problems encoun‐
tered during DNA synthesis or inefficient DNA repair. In addition, telomere shortening is
accelerated by active oxygen species and ultraviolet radiation, which are thought to be major
environmental causes of human telomere shortening [46]. In the next section, we will sum‐
marize our current knowledge concerning the main data available about telomere instability
induced by anticancer drugs on mammalian cells.
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4. Telomere instability produced by anticancer drugs in mammalian cells
In the next sections, we will consider the main data available concerning the short- and long-
term telomere instability induced by anticancer drugs in mammalian cells. Firstly, we will
refer to those drugs whose effects on telomeres have been intensively investigated: bleomy‐
cin, streptonigrin, streptozotocin, paclitaxel, cisplatin, doxorubicin, etoposide and 5-azacyti‐
dine. Afterwards, we will shortly refer to other anticancer drugs whose effects on telomeres
are barely known, such as gemcitabine, C-1027, ICRF-193, melphalan and 5-fluorouracil. It
is important to bear in mind that, in this chapter, when we refer to telomeres, we refer to the
very end of the chromosomes (which, at  the molecular level is  constituted by TTAGGG
repeats and the associated RNA and proteins), not the subtelomeric region of them (constitut‐
ed by telomere-specific sequences located near the telomere). Therefore, we will not refer to
those studies involving the effects of anticancer drugs on the subtelomeric regions of the
chromosomes.
4.1. Bleomycin (BLM), Streptonigrin (SN) and Streptozotocin (STZ)
Several years ago, we carried out in our laboratory a series of experiments to determine the
short-term effects of three antibiotics with anticancer properties, bleomycin (BLM), streptoni‐
grin (SN) and streptozotocin (STZ) on mammalian telomeres and telomeric sequences (see [26]
for review).
BLM (CAS No. 11056-06-7) is a chemotherapeutic drug isolated from Streptomyces verticillus
which is commonly used to treat testicular cancer, lymphoma, lung cancer, cervical cancer and
cancers of the head and neck [50]. This antibiotic is an S-independent clastogen and a radio‐
mimetic agent that generates free radicals and induces single- and double-strand breaks in
DNA [50, 51]. SN (CAS No. 3930-19-6) is an aminoquinone antitumor antibiotic isolated from
cultures of Streptomyces flocculus, which shows antitumor activity against a broad range of
tumors, including breast, lung, head and neck cancer, lymphoma and melanoma [52], although
its use in cancer therapy is very limited because it induces severe and prolonged bone marrow
depression [52]. Despite of being considered a radiomimetic compound, SN is capable of
producing chromosome damage both by S-independent and S-dependent mechanisms [52].
Moreover, SN causes inhibition of topoisomerase II by stabilizing the transesterification
intermediate of the enzyme (called cleavable complex) [52]. STZ (CAS No. 18883-66-4) is is an
antibiotic isolated from Streptomyces achromogenes [53, 54], usually used to experimentally
induce diabetes mellitus in laboratory animals, and it has been considered a potential com‐
pound for the clinical treatment of some malignant diseases, including advanced pancreatic
neuroendocrine tumors and colon cancer. STZ is a potent alkylating agent that directly
methylates DNA, giving rise to chromosome and DNA damage [53, 54]. STZ exerts its
clastogenic effect mainly in an S-dependent manner, inducing both chromatid- and chromo‐
some-type aberrations [53, 54].
The abovementioned studies, perfomed using FISH with a Peptide Nucleic Acid telomere
probe (telomere PNA-FISH) in Chinese hamster cells (CHE cell line), showed that all the above
drugs can induce the formation of incomplete chromosomes and terminal fragments [55-58].
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These observations were made on metaphase cells obtained 18 h after treatment (i.e., in cells
in their first mitosis after treatment) and indicated that, despite of the fact that BLM, SN, and
STZ act on chromosomes in a different way, these drugs can induce short-term telomere
instability by chromosome end loss in mammalian cells. The induction of short-term telomere
instability by BLM was also demonstrated by Benkhaled et al. [59] in human lymphocytes.
More recently, our studies were focused on the effects of these antibiotics on the progeny of
the exposed cells, to determine if telomeres play some role in the long-term chromosomal
instability induced by these drugs and if telomere instability can persist in the exposed cells
for several generations after treatment. To accomplish our goal, we exposed rat cells (ADIPO-
P2 cell line) to a single pulse of BLM, SN or STZ, and determined the type and frequency of
chromosomal aberrations at 18 h (first mitosis after exposure), 10 days and 15 days after
treatment by using PNA-FISH with a telomeric probe.
We found that BLM induces persistent telomere instability in mammalian cells, cytogenetically
manifested as incomplete chromosome elements (i.e., chromosome end loss) and telomere
FISH signal loss and duplication (i.e., telomere dysfunction) ([60] and Paviolo, unpublished
data). In addition, our results suggested that BLM can induce delayed telomere instability in
the form of telomere (end-to-end) fusions. Therefore, we concluded that BLM induces telomere
instability at the chromosome level both by chromosome end loss and telomere dysfunction
[60]. The delayed appearance of dicentric chromosomes and telomere fusions (which produces
dicentric chromosomes without accompanying fragment) that we observed in ADIPO-P2 cells
exposed to BLM suggests that the BFB cycles [27] might play a significant role in the mainte‐
nance of the long-term telomere instability induced by this compound. In effect, by inducing
breakage at terminal regions of chromosomes, resulting in incomplete chromosomes, BLM
could promote genome instability through BFB cycles, which can continue for multiple cell
generations, leading to extensive chromosomal rearrangements in the progeny of the cells
exposed to this compound. According to our data, the persistent telomere instability induced
by BLM in rat cells is neither related to telomerase activity nor telomere length variations ([60]
and Paviolo, unpublished data).
In the case of SN, we found that this drug induces persistent (i.e., up to 15 days after treatment)
telomere dysfunction in ADIPO-P2 cells in the form of additional telomeric FISH signals,
extrachromosomal telomeric FISH signals, and telomere FISH signal loss and duplications [61].
Several studies have provided a large body of evidence indicating that SN directly interacts
with DNA, binding covalently but not interacting into the double helix (see [52] for review).
Therefore, the persistence of the clastogenic action of SN in terms of telomere-associated
aberrations could be due to the formation of a stable complex between SN and the DNA
molecule, which may induce chromosome damage through a persistent cyclic redox process
and the resulting generation of active oxygen species [52]. Moreover, we found that SN causes
persistent inhibition of telomerase activity in rat cells [61]. A decreased telomerase activity
could promote extensive telomere shortening, cytogenetically detected as telomere FISH signal
loss. However, using the Flow-FISH technique, we were able to determine that SN does not
have a persistent effect on telomere length in rat cells, since we observed a transient telomere
lengthening in these cells only at 10 days after treatment (Paviolo, unpublished data). There‐
fore, the precise relationship between telomerase activity, telomere length and telomere
instability in SN-exposed cells remains to be determined.
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It is interesting to note that despite of the fact that both BLM and SN are radiomimetic
compounds, they exhibit some important differences in their long-term effects on telomeres
[60, 61]. First, BLM induces persistent chromosome end loss and telomere dysfunction,
whereas SN induces persistent telomere dysfunction but not persistent chromosome end loss.
Second, BLM induces telomere fusions, whereas SN not. Finally, BLM induces delayed
increase of telomerase activity in mammalian cells, while SN decreases telomerase activity.
Although these discrepancies could be due to differences between SN and BLM in their mode
of action [50-52], further studies will be needed to confirm this assumption.
Finally, we found that also STZ induces persistent telomere dysfunction in rat cells, cytoge‐
netically detected mainly as telomere FISH signal loss and duplications, most of them being
chromatid-type aberrations [62]. We observed that STZ induces significantly more signal loss
than duplications, telomere loss thus being the most significant effect of STZ on telomere
function at the chromosome level in ADIPO-P2 cells. As previously mentioned, telomere FISH
signal loss and duplication were also observed in BLM- [60] and SN-exposed ADIPO-P2 cells
[61]. Therefore, these types of aberrations seem to be the predominant chromosome aberrations
directly related to telomere dysfunction induced by anticancer drugs. In addition, our
experiments with rat cells exposed to STZ showed that this compound also induces long-term
telomere instability in the form of incomplete chromosome elements, as previously observed
in the short-term in Chinese hamster cells [57]. We found that STZ induces a transient increase
in telomere length in ADIPO-P2 cells at 10 days after treatment, a delayed effect not related
with telomerase activity, which remained unchanged in both treated and untreated cells [62].
Therefore, the persistence of chromosomal aberrations related to telomere dysfunction in rat
cells exposed to STZ seems to be unrelated to telomerase activity or telomere length.
Besides the abovementioned studies, other researchers reported additional data on the effect
of BLM on telomeres. No further studies have been made concerning the effects of SN and STZ
on telomeres so far. The most important finding with regard to BLM was that human telomeric
DNA sequences are a major target for this anticancer drug [63, 64]. In effect, these authors
examined the DNA sequence specificity of BLM in a target DNA sequence containing 17
repeats of the human telomeric sequence and other primary sites of BLM cleavage and found
that BLM cleaved primarily at 5’-GT in the telomeric sequence 5’-GGGTTA [63, 64]. The
telomeric region constituted 57% of the 30 most intense BLM damage sites in the DNA
sequence examined, these data indicating that telomeric DNA sequences are a major target for
BLM damage. Previously, by using the Comet-FISH technique (i.e., single cell gel electropho‐
resis or Comet assay in combination with Fluorescent in situ hybridization), with a telomere-
specific PNA probe, Arutyunyan et al. [65] found that BLM and Mitomycin C (MMC, CAS No.
50-07-7) induce breaks in telomere-associated DNA in human lymphocytes. The breakage
frequency for telomeric DNA was found to be proportional to that of the total DNA, which
suggests random induction of DNA breaks by these drugs. A year later, these authors using
the same technique showed that, in human lymphocytes, BLM and also the anticancer drug
cisplatin induce telomere DNA damage [66]. The action of cisplatin on telomeres will be
considered in detail later in this chapter.
The induction of telomere DNA damage by BLM (and also MMC) in mammalian cells was
confirmed by Hovhannisyan et al. [67], who analyzed the effect of these drugs in normal human
leukocytes and three transformed cell lines (HT1080, CCRF-CEM and CHO) using the Comet-
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FISH assay. They found significant differences between these cells with respect to quantita‐
tive head/tail distribution of telomeric signals after BLM exposure, which indicates that the
extent of the telomere DNA damage induced by this compound depends on the cell type.
Recently, Liu et al., studied the effect of BLM and other anticancer drugs on telomeres of a mouse
spermatogonial cell line and found that BLM damages telomeric DNA (as seen by the co-
localization of telomere and gamma-H2AX signals after FISH and immunofluorescence) [68].
4.2. Paclitaxel
Paclitaxel or Taxol (CAS No. 33069-62-4) is an anticancer drug, isolated from the bark of the
Pacific yew Taxus brevifolia, that has been shown to be clinically effective against a wide range
of human cancers, including ovarian, breast, lung and pancreatic cancers [69]. The anticancer
effect of paclitaxel is attributable principally to irreversible promotion of microtubule stabili‐
zation and is hampered upon development of chemoresistance by tumor cells [70, 71].
It has been shown that paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel induce
telomeric associations in a murine metastatic melanoma cell line (K1735, clone X-21), being the
effect of the water-soluble form of paclitaxel more pronounced than the effect of paclitaxel
alone [72]. Two years later, these authors analyzed the effects of the above compounds and
two other water-soluble forms of paclitaxel (sodium-pentetic acid-paclitaxel and polyethylene
glycol-paclitaxel) in the same murine cell line and found that these drugs induce the formation
of telomeric associations [73]. In addition, they found that paclitaxel and its water-soluble
conjugates induce extensive telomere erosion (visualized as reduced telomeric signal intensity
after telomere FISH) but do not change telomerase activity [73]. Therefore, these drugs induce
telomere dysfunction in mammalian cells by producing telomeric associations and telomere
erosion (which means loss of telomeric repeats). Telomeric associations and reduction of
telomeric signal intensity were also observed in Tax-18 and Tax-2-4, two paclitaxel-requiring
mutant Chinese hamster ovary (CHO) cell lines [74]. Moreover, in these cells, cell death was
driven by the loss of telomeric DNA repeats, as shown by the analysis of terminal telomeric
restriction fragments [74]. Telomere erosion induced by paclitaxel can be enhanced by
telomerase inhibitors, such as 3'-azido-3'-deoxythymidine (AZT) [75, 76]. More recently, using
telomerase-deficient cells derived from mTERC−/− (mouse telomerase RNA component-
minus) mice, Park et al. demonstrated that, upon telomere erosion, paclitaxel stimulates
chromosomal fusion and instability in cells with dysfunctional telomeres [77]. Chromosomal
fusions promoted by paclitaxel involve both q- and p-chromosome arms, being the q-arm
fusions both unstable and lethal [77]. These chromosomal fusions occur in response to
microtubule disruption induced by paclitaxel in cells with dysfunctional telomeres [77]. Thus,
telomere dysfunction, rather than telomerase inhibition seems to be essential to sensitize
transformed cells to paclitaxel.
4.3. Cisplatin
Cisplatin (CAS No. 15663-27-1), another well-known anticancer drug, was also found to
interact with telomeric DNA sequences. Ishibashi and Lippard [78] showed that cisplatin can
bind to telomeric repeats: Duplex DNA containing five telomeric repeats treated with cisplatin
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at formal platinum/strand ratios of 5 or 10 in water was platinated with efficiencies of 91.0%
and 76.4%, respectively. More recently, Paul and Murray, using an automated capillary DNA
sequencer investigated the interaction of cisplatin with purified telomeric DNA sequences and
found that cisplatin strongly formed adducts with telomeric DNA sequences [79]. A similar
result was obtained by Murray and Kandasamy, using a plasmid clone containing seven
telomeric repeats and a sequence of ten consecutive guanine bases [80]. Although cisplatin
preferentially damaged the guanine sequence, the telomeric DNA was also a major site of
cisplatin adduct formation [80]. Furthermore, Nguyen et al. analyzed the DNA sequence
specificity of cisplatin in a long telomeric tandem repeat (a human telomeric DNA sequence
containing 17 tandem repeats) and found that the 3’-end of the G-rich strand of the telomeric
repeat was preferentially damaged by this compound [81].
Even though several studies showed that cisplatin inhibits telomerase activity in a specific and
concentration-dependent manner in several types of cancer cells (see [82, 83] for example),
little is known about whether this compound induces telomere instability. Ishibashi and
Lippard [78] by using Analysis of Terminal Restriction Fragment (TRF) Length (by Southern
blot) showed that cisplatin induces telomere loss (shortening) and degradation in HeLa cells.
A recent study from Liu et al. in a mouse spermatogonial cell line, showed that the alkylating
compounds cisplatin and 4-hydroperoxycyclophosphamide (4OOH-CPA, a preactivated
analog of cyclophosphamide, CAS No. 50-18-0) induce telomere dysfunction in mouse cells
[68]. These authors found that these compounds decrease telomerase activity and shorten
telomere length, thus causing telomere dysfunction [68]. Thus, cisplatin and 4OOH-CPA could
induce long-term telomeric loss in mammalian cells, resulting from the inhibition of the
enzyme telomerase.
4.4. Doxorubicin and etoposide
Doxorubicin (also called Adriamycin, CAS No. 23214-92-8) and etoposide (CAS No.
33419-42-0) are both topoisomerase II inhibitors with anticancer properties. As is the case with
BLM and cisplatin, doxorubicin can also bind to human telomeric repeats. In effect, it was
demonstrated that this drug binds to the human telomeric sequence 5'-d[GGG(TTAGGG)
(3)]-3' (21-mer), assuming a G-quadruplex structure in the presence of K(+) [84]. It has been
found that doxorubicin inhibits telomerase activity and shortens mean telomere length in
human hepatoma cells [85]. Thus, it has been proposed that telomerase inhibition and telomere
shortening by doxorubicin may contribute to its efficiency in the treatment of hepatocellular
carcinoma. However, doxorubicin showed no effect on telomerase or telomere length in
human ovarian cancer cells [86], induces telomere dysfunction (as determined by the presence
of end-to-end chromosome fusions and end breaks by conventional staining with Giemsa, not
telomere FISH) and decreases telomerase activity but has no effect on telomere length in breast
tumor cells [87], and decreases telomerase activity in several human breast and stomach cancer
cell lines [88]. Thus, the effect of doxorubicin on telomeres depends on the cell type. Moreover,
it has been shown that doxorubicin induces senescence or apoptosis in rat neonatal cardio‐
myocites by regulating the expression levels of the telomere binding factors 1 and 2: High-dose
doxorubicin strongly reduces TRF2 expression while enhancing TRF1 expression, and it
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determines early apoptosis, whereas low-dose doxorubicin induces downregulation of both
TRF2 and TRF1 [89]. The exposed cells maintain telomere dysfunction and a senescent
phenotype over time and undergo late death. Therefore, this study suggests that doxorubicin
induces telomere dysfunction at the molecular level by regulating the expression levels of TRF1
and TRF2, both of them being part of the shelterin complex. A few years ago, it was reported
that doxorubicin and etoposide induce progressive telomere shortening (assessed by flow-
fluorescence in situ hybridization and Southern blotting) in human mesenchymal stem cells
(MSCs), obtained from bone marrow (BM) cells from normal adults and grown in the presence
of platelet lysates [90]. A year later, Li et al. reported that the treatment of normal human T
lymphocytes and fibroblasts with doxorubicin or etoposide led to significant shortening of
telomeres, down-regulation of telomerase activity, diminished expression of telomerase
reverse transcriptase (hTERT) and the telomere binding proteins TPP1 and POT1 and telomere
dysfunction in these cells [91]. Therefore, both topoisomerase II poisons doxorubicin and
etoposide, induce telomere dysfunction. However, recent data reported by Liu et al. showed
that etoposide alone does not specifically affects telomeres of a mouse spermatogonial cell line
and that this drug did not induce telomere dysfunction in these cells [68], but in combination
with BLM and cisplatinum, etoposide produces telomere shortening in rat male germ cells [92].
In addition, it was demonstrated that etoposide did not affect telomere length in the neuro‐
blastoma cell line SHSY5Y, with very short telomeres and the acute lymphoblastic T cell line
1301, which displays extremely long telomeres [93]. Thus, the effect of etoposide on telomeres
depends on the cell type.
4.5. 5-azacytidine (5-AZA)
5-azacytidine (5-AZA, Ladakamycin, CAS No. 320-67-2) and its deoxy derivative 5-aza-2’de‐
oxycytidine (Decitabine, CAS No. 2353-33-5) are demethylating compounds (inhibit DNA
methyltransferases) with anticancer properties, usually employed against myelodysplastic
syndrome and acute myeloid leukemia [94]. It has been shown that 5-aza-2’deoxycytidine,
either alone or in combination with trichostatin A, induces up-regulation of shelterin genes,
which leads to telomere elongation in breast cancer cell lines [95]. In addition, 5-AZA was
found to induce DNA damage at telomeres and telomere dysfunction in acute myeloid
leukemia cell lines [96]. Telomere dysfunction was coupled with telomere shortening, dimin‐
ished TERT expression and apoptosis in the exposed cells [96]. Thus, these authors suggested
that another mechanism (besides DNA demethylation) by which 5-AZA exerts its anticancer
activity is telomere dysfunction [96]. On the contrary, Choudhury et al., using the glioblastoma
cell line SF-767, found that 5-AZA caused significant changes in DNA methylation of subte‐
lomeric regions of chromosomes but did not modify the telomere length in these cells [97].
Thus, further studies will be needed to clarify the effect of this compound on telomeres.
4.6. Gemcitabine
It has been recently reported that the cytidine analog gemcitabine (2′, 2′-diflurodeoxycytidine)
(CAS No. 95058-81-4), an effective anticancer drug against several types of solid tumors,
including colorectal, breast, pancreatic, renal and lung cancer [98], causes telomere attrition or
shortening in Hela cells, by increasing the level and stability of TRF2 [99], that is required for
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the Xeroderma pigmentosum group F protein (XPF)-dependent telomere loss or degradation.
By increasing TRF2 expression, gemcitabine enhances XPF activity, and because XPF is a
nuclease, binding of the nuclease to telomeres may lead to inappropriate excision of telomeric
DNA. The anticancer effect of gemcitabine is due to the incorporation of the active derivative
compound dFdCTP into DNA in proliferating cells, leading to inhibition of DNA synthesis
and repair. Thus, the above findings by Su et al. [99] suggest that the promotion of telomere
attrition by induction of TRF2 is a new mechanism of action of gemcitabine against cancer.
This effect of gemcitabine seems to be independent of telomerase, since this drug had no effect
on telomerase activity in Hela cells 3 days after treatment. No further studies have been made
to analyze the effect of gemcitabine on mammalian telomeres.
4.7. C-1027
The enediyne antibiotic C-1027 or Lidamycin (CAS No. 120177-69-7) is a new kind of macro‐
molecular antitumor antibiotics, produced by Streptomyces globisporus in soil, consisting of a
noncovalently bound apoprotein and a labile chromophore which is responsible for most of
the biological activities [100-102]. This drug is a potent anticancer drug with radiomimetic
properties, which is being currently evaluated in Phase II clinical trials [103]. Several years ago,
it was demonstrated in cultured human colon carcinoma HCT116 cells exposed to C-1027 that
this drug induces telomere fusions (i.e., chromosomes joined end to end at their telomeres or
fused together after complete loss of telomere sequences) in these cells [104]. Therefore, C-1027
induces short-term telomere dysfunction in human cells. No further studies on the effects of
C-1027 on telomere stability have been performed so far.
4.8. ICRF-193
ICRF-193 ([meso-2, 3-bis (2, 6-dioxopiperazin-4-yl) butane], CAS No. 21416-68-2) is a topoiso‐
merase II catalytic inhibitor [105]. Two recent publications deal with the effect of ICRF-193 on
telomeres [106, 107]. These studies show that this drug induces DNA damage at telomeres (as
assessed by colocalization of telomere PNA-FISH signals and immunofluorescence of 53BP1
foci) [106] and telomere dysfunction in the HT1080 fibrosarcoma cell lines [106] and telomere
shortening in mice cells [107]. In particular, it was found that ICRF-193 induces damage at
telomeres properly capped by TRF2 but not by POT1 [106]. Moreover, ICRF-193 treatment
blocks ALT-associated phenotypes in vitro and inhibits ALT cell proliferation in mice [107],
which suggests that this drug could be used to prevent cell proliferation in cancer cells with
an ALT mechanism of telomere elongation. No further studies on the effects of ICRF-193 on
telomere stability have been performed so far.
4.9. Melphalan
Melphalan, L-phenylalanine mustard, L-PAM, Alkeran or L-Sarcolysine (CAS No. 148-82-3)
is a chemotherapeutic drug belonging to the class of nitrogen mustard alkylating agents [108].
It has been reported that melphalan has no effect on telomerase activity in human testicular
cancer cells [82]. More recently, by studying the induction and persistence of chromosome
aberrations in bone marrow and spleen cells of p53+/- (and wild type) mice exposed for 4, 13,
or 26 weeks to 2 mg/kg melphalan (MLP), Sgura et al. [109] were able to demonstrate that this
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drug induces telomere shortening in bone marrow cells of wild-type mice, while in p53+/- mice
the exposure to this compound induces telomere elongation. No further studies on the effect
of melphalan on telomeres have been reported so far.
4.10. 5-fluorouracil (5-FU)
In the case of 5-fluorouracil (CAS No. 51-21-8), a thymine analog with anticancer properties
commonly used against several types of solid tumors, including breast, colorectal, pancreatic,
skin and cervical carcinoma [110], there is no information about its effects on telomeres as a
single drug, since this compound is usually employed in chemotherapy in combination with
several drugs. Thus, for example, it has been reported that, combined with cisplatin, 5-FU
increases telomerase activity and causes long-term telomere elongation in colorectal carcinoma
cells (LoVo and DLD-1 cell lines) [111]. It is interesting to mention that it has been recently
demonstrated that overexpression of a human telomerase reverse transcriptase polypeptide
(hTERT)C27, which induces telomere dysfunction by promoting end-to-end chromosome
fusions, sensitizes HeLa cells and nasopharyngeal carcinoma cells to 5-FU cytotoxic effects
[112, 113]. Thus, despite the fact that 5-FU does not induce telomere dysfunction, these recent
studies suggest that combinational therapy of this drug with hTERTC27 may provide a novel
approach to treat cancer.
5. Telomere instability induced by anticancer drugs: Conclusions and
future prospects
Even though the studies performed so far demonstrate that a lot of work needs to be done in
order to fully understand the effects of anticancer drugs on telomere stability and function,
some important conclusions can be drawn from these studies.
1. For some drugs (BLM, SN. STZ, paclitaxel, 5-azacytidine, etc.) it is clearly established that
they induce telomere instability (either by chromosome end loss or telomere dysfunction)
in the short- and/or the long-term in mammalian cells, whereas for most of the anticancer
drugs this effect remains to be determined. In fact, the literature reviewed in this chapter
clearly shows that there are very few studies concerning the long-term effect of anticancer
drugs on telomeres. Most of these studies were performed in the last few years. Moreover,
little is currently known about the effect of several chemotherapeutic agents (for example,
cyclophosphamide, mitomycin C and melphalan) on mammalian telomere dynamics,
including potential effects on telomere length, structure, function, telomerase activity, and
telomere shelterin proteins.
2. For some drugs (for example, 5-fluorouracil) it remains to be determined if they induce
telomere instability per se, since the studies performed so far were carried out using these
drugs in combination with other drugs, but not in a single form.
3. For several anticancer drugs (i.e., doxorubicin, etoposide, 5-azacytidine), published data
on the effects of telomeres are contradictory. Thus, additional studies will be needed to
clarify this issue.
Telomere Instability Induced by Anticancer Drugs in Mammalian Cells
http://dx.doi.org/10.5772/64928
131
4. Some drugs (i.e., 5-azacytidine and trichostatin A) could exert its anticancer effect by
inducing telomere lengthening instead of shorthening or erosion. Telomere elongation
induced by these drugs may have the effect of stabilizing the telomere thus reducing the
amount of genetic damage the cell will undergo, thereby stopping the clonal evolution of
the cancer cell population. As a result, these tumors may be more susceptible to further
treatment. Alternatively, the elongation of telomeres in cancer cells may give rise to
chemoresistant tumors.
5. Some anticancer drugs -like paclitaxel- could exert their anticancer effect by inducing
telomere fusions. Thus, this drug could be used to enhance chemosensitivity in cells with
dysfunctional telomeres.
6. Finally, regardless of the underlying mechanism involved in the long-term telomere
instability induced by some anticancer drugs, the data available raise concern about the
potential risks of a long-term chemotherapy based on these drugs. Damage to telomeres
induced by cytostatic therapy theoretically could generate telomere shortening and,
subsequently, induce an additional genomic instability in neoplastic cells, this effect
causing undesirable side effects, including secondary malignancies in long-term survivors
of cancer.
In summary, further studies will be needed to fully elucidate the effects of anticancer drugs
on telomere stability. Depending on the drug, these studies should be aimed at determining
whether it induces short- and long-term telomere instability or not, and if this telomere
instability is due to chromosome breakage or telomere dysfunction. Undoubtedly, these
studies will contribute to a better understanding of the effects of the anticancer drugs on
mammalian telomeres. This information will be of great importance to understand the genomic
instability associated with chemotherapy regimens.
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